ADC Therapeutics
Rue Saint-Pierre 2,
Lausanne
1003
Tel: 1-212-616-4000
Website: http://www.adctherapeutics.com/
Email: info@adctherapeutics.com
195 articles about ADC Therapeutics
-
ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Japan
1/18/2022
ADC Therapeutics SA announced it has entered an exclusive license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of ZYNLONTA® for all hematologic and solid tumor indications in Japan.
-
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
11/9/2021
ADC Therapeutics SA announced today that Chris Martin, PhD, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 16th at 11:20 a.m. GMT / 6:20 a.m. EST.
-
ADC Therapeutics Announces Abstracts to be Presented at the 63rd ASH Annual Meeting
11/4/2021
ADC Therapeutics Announces Abstracts to be Presented at the 63rd ASH Annual Meeting
-
ADC Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates
11/2/2021
ZYNLONTA ® (loncastuximab tesirine-lpyl) third quarter 2021 net sales of $13.1 million
-
ADC Therapeutics Announces Validation of its Marketing Authorization Application by the European Medicines Agency for ZYNLONTA®
10/29/2021
ADC Therapeutics SA today announced its Marketing Authorization Application (MAA) for ZYNLONTA®, a CD19-targeted ADC for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), has been validated by the European Medicines Agency (EMA).
-
ADC Therapeutics to Host Third Quarter 2021 Financial Results Conference Call on November 2, 2021
10/27/2021
ADC Therapeutics to Host Third Quarter 2021 Financial Results Conference Call on November 2, 2021
-
Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Pivotal Phase 2 Clinical Trial for Diffuse Large B-cell Lymphoma
9/29/2021
Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA ® in Pivotal Phase 2 Clinical Trial for Diffuse Large B-cell Lymphoma
-
ADC Therapeutics Doses First Patient in Phase 1 Clinical Trial of ADCT-901 in Advanced Solid Tumors
9/27/2021
ADC Therapeutics SA today announced the first patient has been dosed in the Phase 1 clinical trial evaluating ADCT-901, targeting kidney associated antigen 1 (KAAG1), in patients with selected advanced solid tumors with high unmet medical needs.
-
ADC Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
9/23/2021
ADC Therapeutics SA announced today that Chris Martin, Chief Executive Officer, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Thursday, September 30th at 9:20 a.m. ET.
-
ADC Therapeutics Receives Orphan Drug Designation in Europe for ZYNLONTA®
9/13/2021
ADC Therapeutics Receives Orphan Drug Designation in Europe for ZYNLONTA ®
-
ADC Therapeutics to Participate in Morgan Stanley’s 19th Annual Global Healthcare Conference
9/9/2021
ADC Therapeutics to Participate in Morgan Stanley’s 19th Annual Global Healthcare Conference
-
ADC Therapeutics Enters Into a Financing Agreement with HealthCare Royalty for Up to $325 Million
8/26/2021
ADC Therapeutics SA today announced it had entered into a royalty purchase agreement with HealthCare Royalty Partners (HealthCare Royalty).
-
ADC Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates
8/3/2021
ADC Therapeutics SA, a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates for patients with hematologic malignancies and solid tumors, reported financial results for the second quarter ended June 30, 2021 and provided business updates.
-
ADC Therapeutics Announces Encouraging Interim Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) Presented at the 16th Annual International Conference on Malignant Lymphoma
6/22/2021
ADC Therapeutics Announces Encouraging Interim Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) Presented at the 16 th Annual International Conference on Malignant Lymphoma
-
ADC Therapeutics Presents Updated ZYNLONTA™ (loncastuximab tesirine-lpyl) Clinical Data at 16th Annual International Conference on Malignant Lymphoma
6/18/2021
ADC Therapeutics Presents Updated ZYNLONTA™ (loncastuximab tesirine-lpyl) Clinical Data at 16 th Annual International Conference on Malignant Lymphoma
-
ADC Therapeutics Shareholders Approve All Resolutions at the Annual General Meeting
6/11/2021
ADC Therapeutics SA today announced that shareholders approved all of the resolutions as proposed by the Board of Directors at yesterday's Annual General Meeting.
-
ADC Therapeutics Announces Presentations at the 16th Annual International Conference on Malignant Lymphoma
6/9/2021
ADC Therapeutics SA announced that abstracts on camidanlumab tesirine and ZYNLONTA™ have been selected for presentation at the 16th Annual International Conference on Malignant Lymphoma, which is being held virtually June 18-22, 2021.
-
ADC Therapeutics to Present at Jefferies Virtual Healthcare Conference
5/27/2021
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, announced today that Chris Martin, Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021, at 8:30 a.m. ET.
-
ADC Therapeutics Announces Online Publication of Camidanlumab Tesirine Phase 1 Results in The Lancet Haematology
5/26/2021
Camidanlumab tesirine (Cami) demonstrated anti-tumoral activity response rate in 86% of Hodgkin lymphoma patients at dose currently being evaluated in ongoing pivotal Phase 2 trial
-
Avid Bioservices to Serve as Commercial Manufacturer for ADC Therapeutics’ ZYNLONTA™ (Loncastuximab Tesirine-Lpyl)
5/25/2021
ZYNLONTA™ Recently Approved as First and Only CD19-Targeted Antibody Drug Conjugate for Single-Agent Treatment for Adult Patients with Relapsed or Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL)